Search - tctmd.com

Displaying 441 - 460 of 1865

Sort: Relevancy | Date

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

Case Resolution

Presenter: Tom Cahill

September 18, 2022

Presentation TCT 2022

How Will Emerging Evidence Help Us?

Presenter: Philippe Genereux

September 18, 2022

Presentation TCT 2022

What Do the Guidelines Say?

Presenter: Victoria Delgado

September 18, 2022

Presentation TCT 2022

Case Presentation: A 70 Year-old Low-risk Woman With Asymptomatic Severe Aortic Stenosis

Presenter: Tom Cahill

September 18, 2022

Presentation TCT 2022

Three-Year Outcomes of the Randomized SCOPE I Trial Comparing the ACURATE Neo vs the SAPIEN 3 Transcatheter Heart Valve System in Patients With Symptomatic Severe Aortic Stenosis

Presenter: Jonas Lanz

September 17, 2022

Presentation TCT 2022

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

Presenter: Yu Sato

September 17, 2022

Presentation TCT 2022

TAVR Techniques in Bicuspid Anatomy – Valve Selection, Sizing, and Positioning

Presenter: Didier Tchetche

September 17, 2022

Presentation TCT 2022

Transcatheter Aortic Valve Replacement in Small Aortic Annuli: Results From the FRANCE-TAVI Registry

Presenter: Walid Ben-Ali

September 17, 2022

Presentation TCT 2022

Challenging BAV Anatomy for TAVR – Who NOT to Treat

Presenter: Hasan Jilaihawi

September 17, 2022

Presentation TCT 2022

Update on the Evidence-- We Need a Randomized Trial

Presenter: Rahul Prakash Sharma

September 17, 2022

Presentation TCT 2022

Update on the Evidence – Registries are Enough

Presenter: John K. Forrest

September 17, 2022

Presentation TCT 2022

Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: The PROTECTED TAVR Study

Presenter: Samir Kapadia

September 17, 2022

Presentation TCT 2022

TCT 324: Cerebral Embolic Protection Devices and Outcomes of Transcatheter Aortic Valve Replacement: Insight from National Readmission Database 2017-2019.

Presenter: Ahmed Altibi

September 17, 2022

News Conference News TCT 2022

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

Todd Neale

September 16, 2022

News Conference News TCT 2022

TAVI Sees Rapid Growth for Severe AS Across Age Spectrum in US

Caitlin E. Cox

September 16, 2022

News Daily News

Frailty Before Cardiac Surgery Common, Linked to Adverse Outcomes

Michael O'Riordan

September 13, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

News Opinion CV Team Dispatch

September 2022 News Roundup

L.A. McKeown

September 01, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

Advertisement

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Case Resolution

How Will Emerging Evidence Help Us?

What Do the Guidelines Say?

Case Presentation: A 70 Year-old Low-risk Woman With Asymptomatic Severe Aortic Stenosis

Three-Year Outcomes of the Randomized SCOPE I Trial Comparing the ACURATE Neo vs the SAPIEN 3 Transcatheter Heart Valve System in Patients With Symptomatic Severe Aortic Stenosis

Pathology of Self-Expanding Transcatheter Aortic Valve Failure and Hypo-Attenuated Leaflet Thickening (HALT)

TAVR Techniques in Bicuspid Anatomy – Valve Selection, Sizing, and Positioning

Transcatheter Aortic Valve Replacement in Small Aortic Annuli: Results From the FRANCE-TAVI Registry

Challenging BAV Anatomy for TAVR – Who NOT to Treat

Update on the Evidence-- We Need a Randomized Trial

Update on the Evidence – Registries are Enough

Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement: The PROTECTED TAVR Study

TCT 324: Cerebral Embolic Protection Devices and Outcomes of Transcatheter Aortic Valve Replacement: Insight from National Readmission Database 2017-2019.

HF Devices Have a Role to Play, Even With Today’s GDMT Bonanza

TAVI Sees Rapid Growth for Severe AS Across Age Spectrum in US

Frailty Before Cardiac Surgery Common, Linked to Adverse Outcomes

New Faces, New Formats, New Tech: What to Expect From TCT 2022

September 2022 News Roundup

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content